Traws reported fewer treatment-related adverse events and no viral rebound than PAXLOVID®. That supports its drug, but the report gives no comparison of how well the drugs worked, and FDA discussions have not happened yet.
These findings could help Traws make a case for testing the drug further, especially for people who cannot take PAXLOVID®. The report gives no comparison of how well the drugs worked, and Traws has only said it plans to discuss a path with the FDA. Approval is still unconfirmed.
The report compares Traws' candidate with PAXLOVID®, but gives no evidence that Pfizer's sales or product use have changed. Traws has not yet discussed a registration path with the FDA.
Follow Traws Pharma (TRAW) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for TRAW